Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Rommie Hughes

Vascular Surgery Scottsbluff, NE Medical Doctor

NPI 1427042910 CMS profile 110145

2 W 42Nd St, Suite 3100, Scottsbluff, NE 69361

Open in the dashboard

General payments

$15,465

68 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Rommie Hughes of Scottsbluff, NE is reported in the CMS Open Payments database as having received $15,465 across 68 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 77th percentile of Vascular Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $192 4
2024 General $3,576 9
2023 General $223 5
2022 General $228 4
2021 General $4,710 16
2020 General $5,880 20
2019 General $656 10

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Rommie Hughes
  • Vascular Surgery median
  • Middle half of Vascular Surgery
  • National median

In program year 2025, general payments to Rommie Hughes were reported at $192. Among 3,991 Vascular Surgery profiles paid that year, the median was $924 and the middle half received between $273 and $2,636.

Show as a table
Year Rommie Hughes Vascular Surgery median Middle half National median
2019 $656 $796 $226–$2,363 $163
2020 $5,880 $348 $118–$1,110 $114
2021 $4,710 $471 $158–$1,421 $132
2022 $228 $725 $222–$2,183 $149
2023 $223 $836 $257–$2,440 $160
2024 $3,576 $909 $252–$2,619 $164
2025 $192 $924 $273–$2,636 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Intuitive Surgical, Inc. $13,080 23 payments
  2. Endologix, Inc. $1,753 16 payments
  3. Medtronic Vascular, Inc. $131 5 payments
  4. Medtronic, Inc. $101 6 payments
  5. KLS-Martin L.P. $88 1 payment
  6. LeMaitre Vascular, Inc. $41 2 payments
  7. Davol Inc. $30 1 payment
  8. W. L. Gore & Associates, Inc. $29 1 payment
  9. Bolton Medical Inc $29 1 payment
  10. Allergan Inc. $27 2 payments
  11. Other $157 10 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Education $10,500 4 payments
  2. Food and Beverage $2,528 51 payments
  3. Travel and Lodging $2,437 13 payments
Products named General payments · program years 2019–2025
  1. Da Vinci Surgical System Surgery $6,580 20 payments
  2. Da Vinci Surgical System Surgery $4,000 2 payments
  3. DAVINCI XI $2,500 1 payment
  4. Ovation $850 6 payments
  5. Ovation iX Iliac Stent Graft $704 8 payments
  6. AFX2 Bifurcated Endograft System $118 1 payment
  7. Alto Abdominal Stent Graft System $81 1 payment
  8. Endurant $71 3 payments
  9. ClosureFast $58 1 payment
  10. XENOSURE $41 2 payments
  11. Other $386 23 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 6 drugs

Part D claims

157

Median for General Surgery: 59

Drug cost

$7,594

Median for General Surgery: $393

Branded share of claims

90.4%

Median for General Surgery: 28.9%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 12 $6,160
Clopidogrel Clopidogrel Bisulfate Brand 69 $881
Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen Brand 38 $233
Lidocaine-Prilocaine Lidocaine/Prilocaine Brand 11 $172
Ciprofloxacin Hcl Generic 15 $95
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 12 $54

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 15,891 Part D prescribers listed as General Surgery; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 132 billing codes

Paid by Medicare

$219,589

Medicare's payments for the services billed

Medicare patients

787

Average age 74

Services billed

1,485

409 women, 378 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 43%
Ischemic heart disease 29%
Diabetes 27%
COPD 21%
Chronic kidney disease 20%
Atrial fibrillation 19%
Depression 18%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

68 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Vascular Surgery in Nebraska

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record